[Special Stock] Lunit Surges on Confirmed Clinical Efficacy of Nasopharyngeal Cancer Immunotherapy Combination
[Asia Economy Reporter Lee Seon-ae] The stock price of medical artificial intelligence (AI) company Lunit is soaring. It is interpreted that the news of the application of the AI biomarker 'Lunit SCOPE' to nasopharyngeal cancer patients treated with immuno-oncology drugs being published in the world-renowned cancer research journal 'Clinical Cancer Research' has influenced the stock price.
As of 9:18 a.m. on the 2nd, Lunit is trading at 41,450 KRW, up 6.42% from the previous trading day. It surged to 41,900 KRW in early trading.
On the 1st, Lunit conducted a phase 2 clinical trial of combination therapy with the immuno-oncology drug 'Nivolumab' and the conventional anticancer drug 'Gemcitabine' on 36 nasopharyngeal cancer patients at eight domestic hospitals. During the analysis process, Lunit's product 'Lunit SCOPE' was applied to predict patients' responses, revealing that classifying immune phenotypes in nasopharyngeal cancer can predict the therapeutic effect of immuno-oncology drugs in advance. Accordingly, investor expectations appear to be growing.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- 59% of Americans Say "U.S. Prime Has Already Passed"... 44% Pessimistic About Next 50 Years
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Seobum Seok, CEO of Lunit, said, "This study will greatly help predict the therapeutic effect of immuno-oncology drugs on nasopharyngeal cancer, which has not been extensively studied so far, and develop new treatments. It is meaningful in that it showed the possibility of using Lunit SCOPE not only in immuno-oncology monotherapy but also in actual clinical settings conducted with combination therapy with conventional anticancer drugs."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
